ウイルスの不活性化 市場 | サイズ分析・成長・展望 (2022-2030)

Table of Content

1.Introduction

1.1.Market Introduction
1.2.Market Research Methodology
1.2.1.Research Process
1.2.2.Primary Research
1.2.3.Secondary Research
1.2.4.Data Collection Technique
1.2.5.Data Sources
1.3.Market Estimation Methodology
1.3.1.Limitations of the Study
1.4.Product Picture of Viral Inactivation
1.5.Global Viral Inactivation: Classification
1.6.Geographic Scope
1.7.Years Considered for the Study
1.8.Research Methodology in brief
1.9.Parent Market Overview
1.10. Overall Viral Inactivation Market Regional Demand
1.11. Research Programs/Design
1.12. Market Breakdown and Data Triangulation Approach
1.13. Data Source
1.14. Secondary Sources
1.15. Primary Sources
1.16. Primary Interviews
1.17. Average primary breakdown ratio

2.Market Dynamics

2.1.Drivers
2.1.1.Drivers
2.2.Restraints
2.2.1.Restraints
2.3.Opportunity
2.3.1.Impact forces on market dynamics
2.3.2.Impact forces during the forecast years
2.4.Industry Value Chain
2.4.1.Upstream analysis
2.4.2.Downstream analysis
2.4.3.Distribution Channel
2.4.4.Direct Channel
2.4.5.Indirect Channel
2.5.Potential Customers
2.6.Manufacturing/Operational Cost Analysis
2.7.Pricing Analysis by Region
2.8.Key Technology Landscape
2.9.Regulatory Analysis
2.10. Porter\'s Analysis
2.10.1.Supplier Power
2.10.2.Buyer Power
2.10.3.Substitution Threat
2.10.4.Threat from New Entry
2.10.5.Competitive Rivalry
2.11. PESTEL Analysis
2.12. Political Factors
2.13. Economic Factor
2.14. Social Factors
2.15. Technological Factor
2.16. Environmental Factors
2.17. Legal Factor

3.Global Viral Inactivation Market Segmentation, by Revenue (USD Million), (2023-2030)

3.1.By Method
3.1.1.Solvent/Detergent Inactivation
3.1.2.Pasteurization (Heating)
3.1.3.Acidic pH Inactivation
3.2.By Product
3.2.1.Kits
3.2.2.Reagents
3.2.3.Systems
3.2.4.Services
3.3.By Application
3.3.1.Blood & Blood Products
3.3.2.Stem Cell Products
3.3.3.Tissue & Tissue Products
3.3.4.Vaccines and Therapeutics
3.3.5.Cellular & Gene Therapy Products
3.4.By End Use
3.4.1.Contract Research Organizations
3.4.2.Pharmaceutical and Biotechnology Companies
3.4.3.Academic Research Institutes
3.4.4.Others

4.Global Viral Inactivation Market Overview, By Region

4.1. North America Market Revenue (USD Million), by Countries, (2023-2030)
4.1.1. US
4.1.1.1.By Method
4.1.1.2.By Product
4.1.1.3.By Application
4.1.1.4.By End Use
4.1.2.Germany
4.1.3.Spain
4.1.4.Russia
4.1.5.Italy
4.1.6.BENELUX
4.2.Asia Pacific Market Revenue (USD Million), by Countries, (2023-2030)
4.2.1. China
4.2.2. Japan
4.2.3. Australia
4.2.4. South Korea
4.2.5. India
4.2.6. ASIAN
4.3.Latin America Market Revenue (USD Million), by Countries, (2023-2030)
4.3.1. Brazil
4.3.2. Argentina
4.3.3. Chile
4.4.Middle East and Africa Market Revenue (USD Million), by Countries, (2023-2030)
4.4.1.GCC
4.4.2.Turkey
4.4.3.South Africa

5.Global Viral Inactivation Market Revenue: Competitive Analysis, 2022

5.1.Key strategies by players
5.2.Revenue (USD Million and %), By manufacturers, 2022
5.3.Player Positioning by Market Players, 2022

6.Competitive Analysis

6.1.Thermo Fisher Scientific Inc.
6.1.1.Business Overview
6.1.2.Business Financials (USD Million)
6.1.3.Product Category, Type, and Specification
6.1.4.Main Business/Business Overview
6.1.5.Geographical Analysis
6.1.6.Recent Development
6.1.7.Swot Analysis
6.2.Sigma-Aldrich (Merck KGaA)
6.3.VWR International, LLC
6.4.Pall Corporation (Danaher Corporation)
6.5.Rad Source Technologies
6.6.Sartorius AG
6.7.Texcell
6.8.WuXi Biologics
6.9.Macopharma

7.Market Research Findings & Conclusion
Disclaimer

Disclaimer